Anika Therapeutics' CEO Discusses Q4 2011 Results - Earnings Call Transcript

Anika Therapeutics Inc. (ANIK)

Q4 2011 Earnings Call

March 01, 2012 01:00 PM ET


Kevin Quinlan – CFO

Chuck Sherwood – President & CEO


Mark Landy

Jim Gentrup – Discovery Investment Research

John Parsons – Private Investor

Neil Gore



Good day, ladies and gentlemen, and welcome to the Fourth Quarter 2011 Anika Therapeutics Incorporated Earnings Conference Call. My name is Shenele and I’ll be your operator for today. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer session. (Operator Instructions). As a reminder, this conference is being recorded for replay purposes.

I would now like to turn the conference over to Mr. Kevin Quinlan, Chief Financial Officer. Please proceed.

Kevin Quinlan

Thank you, Shenele, and good afternoon everyone. If you’ve not received a copy of the Anika news release, which was issued after the market closed last evening or you would like to be added to our contact list, please contact Sharon Merrill Associates at 617-542-5300. The news release is also posted in the Investor Relations section of our website at

Also, I want to mention that we have slides posted on the Anika website that illustrates some of the points we’ll be covering during today’s call. These slides can be found on the Investor Relations section under the Events, Webcasts & Presentations tab. We invite you to take a moment to open the file and follow the presentation along with us.

Please turn to slide number two. Before we begin, please remember that statements made in this call, which are not statements of historical fact, are forward-looking statements as defined in the Securities Exchange Act of 1934. Words such as will, believe, appear, plan, expect, anticipate, forward, seek, continue, target, goals, objectives, on track, intend, pursue, outlook, as well as other expressions, which are predictions or indications of future events or trends and which do not constitute historical matters identify forward-looking statements.

If you liked this article you might like

Biotech Movers: Anika Up on Strong Analyst Ratings

'Mad Money' Lightning Round: Smith and Wesson Represents Value, Cramer Says

Jim Cramer's 'Mad Money' Recap: How Powerful Are GE, Royal Dutch Shell and Occidental?

Here's Whats Next for Anika Therapeutics Post-Breakout